UDUlrike Denzer

Ulrike Denzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ulrike Denzer has a total of 406 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oncologic Decision after Endoscopic Resection of Gastrointestinal Malignancies: Interdisciplinary Discussion

    by Konstantinos Kouladouros, Michael J. Bourke, Ulrike Denzer, Alanna Ebigbo, Mathieu Pioche, Arthur Schmidt, Naohisa Yahagi

    DenzerIn view of longer life expectancy, endoscopic resection of malignant GI lesions at an early stage is also becoming increasingly important for the

  • Kolorektale NEN (ohne Fernmetastasen)

    by Anja Rinke, Ulrike Walburga Denzer

  • Open Access

    Endoscopic ultrasound-fine needle biopsies of pancreatic lesions: Prospective study of histology quality using Franseen needle

    by Petros Stathopoulos, Anika Pehl, Lutz Philipp Breitling, Christian Bauer, Tobias Grote, Thomas Mathias Gress, Carsten Denkert, Ulrike Walburga Denzer

    Endoscopic ultrasound-fine needle biopsies of pancreatic lesions: Prospective study of histology quality using Franseen needle


  • Open Access

    An Interdisciplinary Approach to Acute and Chronic Pancreatitis: Is There Anything New?

    by Ulrike W. Denzer, Marc G. Besselink

    The current issue of Visceral Medicine addresses the topic of acute and chronic pancreatitis. Even though different etiological or genetic risk factors can induce pancreatitis, clinicians often face similar, potentially severe complications in the acute or chronic course of the disease. Until now a targeted anti-inflammatory medical therapy is lacking. Therefore, any preventive and therapeutic efforts are limited mainly to symptomatic conservative and interventional strategies. This issue offers an overview to the different etiologic, clinical, and therapeutic aspects of the disease as of the current state of science.

  • Endoscopic retrograde cholangiography and percutaneous transhepatic cholangiodrainage in biliary strictures after liver transplantation: Long‐term outcome predictors and influence on patient survival

    by Melina Heinemann, Bita Tafrishi, Sven Pischke, Lutz Fischer, Thomas Rösch, Ansgar W. Lohse, Martina Sterneck, Ulrike W. Denzer

    Background & Aims: Biliary strictures are common complications after orthotopic liver transplantation. Endoscopic retrograde cholangiography evolved as standard and percutaneous transhepatic cholangiodrainage as alternative therapy. This study analysed predictors of long‐term success of biliary strictures after endoscopic retrograde cholangiography and/or percutaneous transhepatic cholangiodrainage and its impact on patient survival.Methods: All adult patients with biliary strictures receiving endoscopic retrograde cholangiography and/or percutaneous transhepatic cholangiodrainage between 2009 and 2015 at the University Medical Center Hamburg‐Eppendorf were retrospectively analysed. Potential predictors of long‐term success (≥12 months) were identified by univariate and logistic regression analyses. Patient survival was analysed by Kaplan‐Meier method and log‐rank test.Results: Hundred and sixteen patients were treated with endoscopic retrograde cholangiography and/or percutaneous transhepatic cholangiodrainage, including 67 patients with anastomotic strictures, 22 with nonanastomotic strictures and 27 with both stricture types. Eighty‐five patients received endoscopic retrograde cholangiography, 17 percutaneous transhepatic cholangiodrainage and 14 both techniques. Long‐term success was achieved in 60 patients (52%). Predictors of treatment failure were a preinterventional C‐reactive protein >8 g/dL in anastomotic strictures (P = 0.039) and a body mass index ≤21 kg/m2 in nonanastomotic strictures (P = 0.021). In patients who received endoscopic retrograde cholangiography only, balloon dilatation of anastomotic strictures with larger diameters favoured success (P = 0.015). Achievement of long‐term success was associated with prolonged patient survival in anastomotic strictures (P = 0.036) and nonanastomotic strictures (P = 0.025), but not in combined strictures (P = 0.739).Conclusion: In post‐orthotopic liver transplantation biliary strictures treated by endoscopic retrograde cholangiography and/or percutaneous transhepatic cholangiodrainage, patient BMI and preinterventional C‐reactive protein may influence prognosis. Endoscopic retrograde cholangiography with larger balloon diameter may favour success in anastomotic strictures. Long‐term success by endoscopic retrograde cholangiography and/or percutaneous transhepatic cholangiodrainage is associated with superior survival in patients with anastomotic strictures and nonanastomotic strictures only.


  • Verlauf von HEV-Virämie und anti-HEV IgM/IgG-Antwort bei 27 immunkompetenten Blutspendern

    by C Kraef, C Schlein, J Hiller, D Westhölter, U Denzer, T Horvatits, S Peine, Aw Lohse, M Luetgehetmann, S Polywka, et al.

    Einleitung: Weltweit kommt es jedes Jahr zu etwa 20 Millionen Hepatitis E Virus Infektionen. Der Verlauf der Virämie und der immunologischen Reaktion bei subklinischen HEV-Infektionen (z.B. Blutspendern) ist bisher unzureichend verstanden. Ziele: Die Beschreibung des Verlaufs der HEV-Virämie und assoziierten Epitop-spezifischen B-Zell-Antwort bei asymptomatischen Blutspendern. Methodik: 27 virämische Blutspender wurden mittels PCR während des Routine-Screenings auf HEV (etabliert 9/2017) identifiziert. Der Verlauf der Viruslast wurde mittels RT-PCR und die Präsenz von Epitop-spezifischer anti-HEV IgM/IgG mittels eines kommerziell verfügbaren Immunoblot-Test (Mikrogen®) untersucht. Ergebnis: Nur 29,6% der virämischen Blutspender hatten eine nachweisbare anti-HEV IgM (22,2%) oder anti-HEV IgG (7,4%) Antwort zum Zeitpunkt der Spende. Mindestens drei der Blutspender waren noch nach mehr als 100 Tagen nachweisbar virämisch (Abb. 1). Alle 27 Spender konnten das HEV innerhalb einer medianen Zeitspanne von 57 Tagen spontan eliminieren. Die anti-HEV IgG Antwort zeigte bei allen Spezifität für das immunogene Epitop O2C (Abb. 2). Schlussfolgerung: Die rein serologische Testung von Blutprodukten auf HEV ist unzureichend. Akute HEV Infektionen bei Blutspendern können mehr als 100 Tage anhalten. Der enge zeitliche Zusammenhang der Viruselimination mit dem Auftreten von anti-HEV IgM/IgG unterstreicht den Stellenwert der B-Zell-Antwort in der Viruselimination. Eine zentrale Rolle scheint dabei die Antwort gegen das immunogene Epitop O2C des HEV zu spielen. Dieses ist auch Teil des in China zugelassenen HEV-Impfstoffes (Hecolin®).

  • Diagnostik bei Cholelithiasis

    by U. Denzer

  • Transfusion-transmitted hepatitis E virus infections: a risk for immunosuppressed patients

    by D Westhölter, J Hartl, J Hiller, U Denzer, S Peine, F Ayuk, M Rybszynski, S Polywka, A Lohse, M Lütgehetmann, et al.

    Question: Hepatitis E is a major threat for immunosuppressed patients, as chronic HEV infection with possibly life-threatening complications might occur. The relevance of blood borne hepatitis E virus (HEV) infections for these patients has been discussed controversially within the last months and still requires further investigations. Methods: All immunosuppressed patients at our center with an HEV infection between 2011 and 2017 were retrospectively studied (n = 37). All blood products given to chronically HEV infected patients were retrospectively analyzed for the presence of HEV RNA by in-house realtime PCR (LLoD 12 IU/ml). Results: 11 immunosuppressed patients (11/37, 30%) developed chronic HEV infection. In 4/11 (36%) we were able to identify an HEV positive blood donation as source of HEV transmission. Interestingly two of the chronic HEV infected patients, who were infected by blood-borne transmission, were heart transplant recipients. Both had been treated with a combination of plasmapheresis and rituximab for humoral rejection. As these cases attracted our attention to this proceeding, we tested the remaining 3 heart transplant recipients who were treated according to the same protocol at our center within the last 5 years but none of them had acquired persistent HEV infection. Conclusions: Blood products are a relevant source of HEV-infection for immunosuppressed individuals and in our series they are responsible for 36% of chronic HEV infections. Thus, we recommend screening of all blood products given to transplant or immunosuppressed recipients for HEV-RNA.

  • Does long-term remission by endoscopic treatment modalities benefit patient and graft survival in biliary strictures after liver transplantation?

    by M Heinemann, B Tafrishi, S Pischke, L Fischer, T Rösch, A Lohse, M Sterneck, U Denzer

    Question: Biliary strictures are among the most common complications after orthotopic liver transplantation (OLT). Recent studies report an increased rate of graft loss and mortality in patients with biliary complications. Interventional endoscopic retrograde cholangiography (ERC) evolved as the standard treatment in most centres, while percutaneous transhepatic cholangiodrainage (PTCD) is available as an alternative approach. This study aims to determine the impact of long-term remission of biliary strictures by ERC and PTCD on patient and graft survival. Methods: All adult patients who received ERC or PTCD for biliary strictures after OLT between 2009 and 2015 were retrospectively analysed. Long-term remission was defined as no need of intervention for at least 12 months. The impact of long-term remission on patient and graft survival was investigated using the Kaplan-Meier method with log-rank test. Patient survival was calculated from diagnosis of biliary stricture to death or last follow-up, graft survival was defined as the time from stricture diagnosis to re-transplantation or last follow-up. Survival was adjusted for age, gender, primary liver disease and type of biliary stricture using inverse probability weighting. Results: A total of 116 patients who were treated with ERC or PTCD for biliary strictures were identified, including 55 patients with anastomotic stricture, 21 with non-anastomotic strictures and 23 with both stricture types. While 86 of 116 patients (74%) were treated by ERC alone, 17 (15%) received PTCD and 13 (11%) were treated with both techniques. Long-term remission was achieved in 60 of 116 patients (52%). After a follow-up time of up to 7.4 years (median, 2.9 years) from diagnosis of biliary stricture, the patient survival was 81% and the graft survival 96%. Patient survival was superior if long-term remission was achieved (median, 3.8 versus 1.8 years, p < 0.001). Also, the graft survival rate was higher after remission (median, 3.8 versus 1.3 years, p = 0.039). Conclusion: Long-term remission of post-transplantation biliary strictures by ERC or PTCD is associated with superior patient and graft survival.

  • Blood-borne HEV transmission: A one year experience with routine HEV screening at a tertiary center

    by M Lütgehetmann, J Hiller, U Denzer, D Westhölter, S Peine, S Polywka, A Lohse, S Pischke

    Background: Routine hepatitis E virus (HEV) testing of blood products has recently been implemented in Great-Britain and the Netherlands. The relevance of blood-borne HEV-transmission in Germany is still under debate and requires further investigations. Methods: Starting in October 2016 all blood donors at the University Hospital Hamburg-Eppendorf were routinely screened for HEV RNA. Pools of 24 donations were tested using the new Roche cobas 6800® HEV PCR assay (LLOD single: 19 IU/ml, 24 pool: 456 IU/ml), reactive pools were tested individually to identify HEV RNA positive donors. HEV RNA positive blood products were not transfused. HEV-PCR positive donors and a control cohort (n = 256) were asked to answer a questionnaire. Results: 30/28981 HEV-RNA-positive donors were identified (0.103%). Median viral load was 960 IU/ml. Only 3 of the positive donors (10%) presented with elevated transaminases at time of donation (ALT: 83 U/l, 192 U/l and 101 U/l). The questionnaire revealed that HEV-viraemic donors significantly more often consumed raw pork meat (12/19; 63%) than controls (89/256, 35%, p < 0.013). In two donors undercooked pork liver dishes were identified as the source of infection. Conclusions: Incidence of HEV RNA in asymptomatic blood donors in our cohort is higher than reported before although most donors have low viral load. Since prolonged viremia (more than 3 months) can be observed, a single HEV-positive blood donor can cause HEV infections in several patients with possible fatal clinical outcome. Uncooked or undercooked pork meat might be a relevant risk factor for HEV infection.